Navigation Links
Seahorse XF96 Extracellular Flux Analyzer Wins Best New Product Award for DRUG DISCOVERY at 2009 Molecular Medicine Conference

BILLERICA, Mass., March 12 /PRNewswire/ -- Seahorse Bioscience, Inc., leader in the real-time measurement of cellular bioenergetics, announced today that the XF96 Extracellular Flux Analyzer, the first analytical instrument for the kinetic measure of mitochondrial oxygen consumption and cytoplasmic glycolysis in a 96-well microplate, was selected as the Best New Product for Drug Discovery Assays & Kits by researchers at the Molecular Medicine Tri-Conference in San Francisco.

"The XF96 Analyzer has revolutionized the way we approach toxicity screening," said Yvonne Will of Pfizer's Compound Safety Prediction Group, who spoke about mitochondrial toxicity at the conference and one of the first users of the XF96. "Since getting the high throughput capabilities of the XF96 Analyzer, we routinely generate 6 point cellular bioenergetic EC50's on our drug candidates - something that just wasn't possible before."

XF Analyzers enable researchers to simultaneously measure the two major energy-producing pathways of the cell in real-time, delivering easy-to-use, information-rich bioenergetic assays to study and develop treatments for obesity, diabetes, ageing and cancer, and to screen for mitochondrial toxicity.

The XF96 Analyzer offers the distinct advantage of making it possible to perform these complex bioenergetic assays in a 96-well microplate. XF Analyzers replace Clark-type electrodes, oxygen or pH sensitive dyes, and radiolabeled substrates.

"Prior to the introduction of our XF instruments the standard method for oxygen measurements was using a Clark electrode, invented in 1953, and a flask of millions of cells," stated Steve Chomicz, Seahorse VP Sales & Marketing. "The XF is the new standard and this award mirrors the positive response we experience everyday from researchers struggling to measure cellular bioenergetics. Seahorse and the XF development team are delighted with CHI's recognition of the value of the XF platform."

About Seahorse Bioscience

Seahorse XF instruments have become the new standard in cellular bioenergetic measurements. Scientists worldwide use these tools to advance their research in understanding the role of mitochondrial function in obesity, diabetes, ageing, cancer, cardiovascular function and safety toxicity. Founded in 2001, Seahorse is headquartered in Billerica, MA. For more information, please visit

    Media Contact: Cynthia Egan
    Phone: 978.671.1610

SOURCE Seahorse Bioscience, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Seahorse Bioscience Enters into Agreement with Primetech Corporation to Bring XF Technology to Japanese Market
2. Extracellular protein sensitizes ovarian cancer cells to chemotherapy
3. Abaxis Launches The VetScan(R) HM5 a State-of-the-Art 5-Part Differential Veterinary Hematology Analyzer
4. Abbott Broadens Use of i-STAT Handheld Blood Analyzer with CLIA Waiver Granted by FDA for CHEM8+ Test Cartridge
5. New Gas Analyzer Measures Two Gases at Once!
6. Sysmex America Receives FDA Clearance for XE-5000(TM) Hematology Analyzer
7. China Medical Technologies Receives CE Mark for Two ECLIA Analyzers and 15 Reagents
8. PATHFAST(R): Rapid Whole Blood Immunoassay Analyzer from Polymedco
9. AutoGenomics INFINITI Analyzer Receives Artistic Design Award
10. Escalon(R) Receives FDA 510(k) Clearance to Market the LIASYS(TM) Clinical Chemistry and Immunoturbidimetric Analyzer
11. CareAnalyzer From DST Health Solutions Helps Health Plans Improve Care Management and Quality for Members
Post Your Comments:
(Date:10/12/2017)... ... 12, 2017 , ... IsoComforter, Inc. ( ), one of ... innovative new design of the shoulder pad. The shoulder pad provides optimal support ... your pain while using cold therapy. By utilizing ice and water that is circulated ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... for the 49th Congress of the International Society of Paediatric Oncology (SIOP) ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. ...
(Date:10/12/2017)... ... 2017 , ... Health Literacy Innovations (HLI), creator of the ... the Cancer Patient Education Network (CPEN), an independent professional organization that shares best ... alliance. , As CPEN’s strategic partner, HLI will help support CPEN members ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... Dining at the University of California Berkeley, and other leading institutions in announcing ... buying power of institutions to change the way animals are raised for food. ...
Breaking Medicine News(10 mins):
(Date:9/19/2017)... 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, ... three leadership team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has ...
(Date:9/18/2017)... PROVIDENCE, R.I. , Sept. 18, 2017 ... in the fields of bioinformatics and immune ... to develop a protective avian influenza A (H7N9) vaccine. ... is distantly related to seasonal influenza and ... approaches, which rely on prior exposure to be ...
(Date:9/12/2017)...  Consumer reviews on the independent review site Consumer Affairs ... company for hearing aids, ranking it higher than Miracle Ear ... ... For Hearing Aids ... online store that provides high performance, state-of-the-art, German-engineered hearing aids directly ...
Breaking Medicine Technology: